A novel type of drug, sodium-glucose cotransporter-2 (SGLT2) inhibitors, has been approved for diabetes treatment by the U.S. Food and Drug Administration (FDA) since 2014 [1]. The gene discussed is SLC5A2; the disease is diabetes mellitus.